Related coverage linked through entity extraction aliases.
Aug 02, 2026
New research advances sustainable biotechnology: recreating poisonous plant compounds for medicine, a two-step fermentation that removes up to 99% of off-putting smells, and hybrid plants that cut carbon footprints by 62%.
Jul 30, 2026
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Jul 03, 2026
The FDA will allow food makers to claim "no artificial colors" as long as dyes are not petroleum-based, even if products contain titanium dioxide. Health experts warn the labeling deceives consumers, as naturally derived additives like titanium dioxide pose health risks and remain unregulated.
Jun 05, 2026
Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.
Jun 01, 2026
The treatment landscape for multiple myeloma is evolving rapidly with T-cell engaging therapies like bispecific antibodies and CAR T-cell treatments shifting care toward a chronic condition with potential treatment breaks. This evolution is creating new side effect management challenges and complicating clinical trial design as sponsors grapple with selecting comparator arms and adapting to a rapidly shifting standard of care.
Mar 28, 2026
Autolus Therapeutics reported $74.3 million in 2025 revenue during its first commercial year, while facing a -265% gross margin. The company aims to achieve positive margins by 2026 through scaling production and expanding into autoimmune diseases with promising early lupus trial results. The broader CAR-T therapy market is projected to reach $9.85 billion in the US by 2033.
Mar 20, 2026
A study of 366 patients found ide-cel CAR-T cell therapy achieved 81.6% overall response rate in patients 70 or older with relapsed/refractory multiple myeloma, with median progression-free survival of 18.9 months versus 5.7 months with standard regimens.
Mar 19, 2026
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Feb 25, 2026
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
Feb 25, 2026
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
Feb 14, 2026
Retrospective analysis of the ZUMA-2 trial found that previous ibrutinib exposure was associated with improved progression-free survival after brexucabtagene autoleucel treatment in mantle cell lymphoma patients, though with increased toxicity.
Feb 15, 2026
CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.
